NO2011007I2 - Ticagrelor eller et farmasøytisk akseptabelt salt derav - Google Patents

Ticagrelor eller et farmasøytisk akseptabelt salt derav

Info

Publication number: NO2011007I2
Authority: NO; Norway
Prior art keywords: ticagrelor; pharmaceutically acceptable; acceptable salt; salt; pharmaceutically
Prior art date: 1998-12-04

Application number

NO2011007C

Other languages

English (en)

Other versions

NO2011007I1 (no

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-04

Filing date

2011-05-23

Publication date

2012-07-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2011007(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-12-04 Priority claimed from SE9804211A external-priority patent/SE9804211D0/xx

1999-04-09 Priority claimed from SE9901271A external-priority patent/SE9901271D0/xx

2011-05-23 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2011-06-06 Publication of NO2011007I1 publication Critical patent/NO2011007I1/no

2012-07-09 Publication of NO2011007I2 publication Critical patent/NO2011007I2/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

NO2011007C 1998-12-04 2011-05-23 Ticagrelor eller et farmasøytisk akseptabelt salt derav NO2011007I2 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE9804211A SE9804211D0 (sv)	1998-12-04	1998-12-04	Novel compounds
SE9901271A SE9901271D0 (sv)	1999-04-09	1999-04-09	Novel compounds
PCT/SE1999/002256 WO2000034283A1 (en)	1998-12-04	1999-12-02	Novel triazolo(4,5-d)pyrimidine compounds

Publications (2)

Publication Number	Publication Date
NO2011007I1 NO2011007I1 (no)	2011-06-06
NO2011007I2 true NO2011007I2 (no)	2012-07-09

Family

ID=26663448

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO20012725A NO319806B1 (no)	1998-12-04	2001-06-01	Nye triazolo(4,5-D)pyrimidinforbindelser, fremgangsmate til fremstilling derav, farmasoytiske preparater som inneholder slike forbindelser og mellomprodukter.
NO2011007C NO2011007I2 (no)	1998-12-04	2011-05-23	Ticagrelor eller et farmasøytisk akseptabelt salt derav
NO2022007C NO2022007I1 (no)	1998-12-04	2022-03-23	Ticagrelor eller et farmasøytisk akseptabelt salt derav - forlenget SPC

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO20012725A NO319806B1 (no)	1998-12-04	2001-06-01	Nye triazolo(4,5-D)pyrimidinforbindelser, fremgangsmate til fremstilling derav, farmasoytiske preparater som inneholder slike forbindelser og mellomprodukter.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2022007C NO2022007I1 (no)	1998-12-04	2022-03-23	Ticagrelor eller et farmasøytisk akseptabelt salt derav - forlenget SPC

Country Status (36)

Country	Link
US (12)	USRE46276E1 (no)
EP (5)	EP1386909A1 (no)
JP (4)	JP4202607B2 (no)
KR (4)	KR100776484B1 (no)
CN (1)	CN1128801C (no)
AR (3)	AR023920A1 (no)
AT (3)	ATE261970T1 (no)
AU (1)	AU766618B2 (no)
BR (1)	BRPI9915883B8 (no)
CA (1)	CA2351709C (no)
CY (3)	CY1110501T1 (no)
CZ (3)	CZ300280B6 (no)
DE (4)	DE122011100004I1 (no)
DK (3)	DK1386921T3 (no)
EG (1)	EG24814A (no)
ES (3)	ES2318081T3 (no)
FR (1)	FR11C0016I2 (no)
HK (3)	HK1061246A1 (no)
HU (2)	HU228589B1 (no)
ID (1)	ID29927A (no)
IL (6)	IL143232A0 (no)
LT (1)	LTPA2011004I1 (no)
LU (1)	LU91819I2 (no)
MY (1)	MY121867A (no)
NO (3)	NO319806B1 (no)
NZ (1)	NZ511778A (no)
PL (1)	PL201283B1 (no)
PT (2)	PT1386921E (no)
RU (3)	RU2317990C2 (no)
SA (1)	SA99200848B1 (no)
SI (3)	SI1135391T1 (no)
SK (1)	SK286007B6 (no)
TR (1)	TR200101567T2 (no)
TW (1)	TWI229674B (no)
WO (1)	WO2000034283A1 (no)
ZA (1)	ZA200104094B (no)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI229674B (en)	1998-12-04	2005-03-21	Astra Pharma Prod	Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9903290D0 (sv) *	1999-09-15	1999-09-15	Astra Pharma Prod	Novel compounds
SE9904129D0 (sv)	1999-11-15	1999-11-15	Astra Pharma Prod	Novel compounds
SE9904377D0 (sv) *	1999-12-01	1999-12-01	Astra Pharma Prod	Pharmaceutical combinations
TWI290549B (en) *	2000-06-02	2007-12-01	Astrazeneca Ab	Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
GB0013407D0 (en) *	2000-06-02	2000-07-26	Astrazeneca Ab	Forms of a chemical compound
GB0013488D0 (en) *	2000-06-02	2000-07-26	Astrazeneca Ab	Chemical compound
US7115585B2 (en)	2000-08-21	2006-10-03	Inspire Pharmaceuticals, Inc.	Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en)	2000-08-21	2006-03-28	Inspire Pharmaceuticals, Inc.	Composition and method for inhibiting platelet aggregation
US7132408B2 (en)	2000-08-21	2006-11-07	Inspire Pharmaceuticals, Inc.	Composition and method for inhibiting platelet aggregation
US6897201B2 (en)	2000-08-21	2005-05-24	Inspire Pharmaceuticals, Inc.	Compositions and methods for the treatment of glaucoma or ocular hypertension
US7452870B2 (en)	2000-08-21	2008-11-18	Inspire Pharmaceuticals, Inc.	Drug-eluting stents coated with P2Y12 receptor antagonist compound
SE0101932D0 (sv) *	2001-05-31	2001-05-31	Astrazeneca Ab	Pharmaceutical combinations
US7435724B2 (en)	2002-02-27	2008-10-14	Inspire Pharmaceutical, Inc.	Degradation-resistant mononucleoside phosphate compounds
MXPA06000675A (es)	2003-07-24	2006-04-19	Astellas Pharma Inc	Derivado de quinolona o sal del mismo.
SE0401001D0 (sv)	2004-03-31	2004-03-31	Astrazeneca Ab	Chemical process
SE0400873D0 (sv) *	2004-03-31	2004-03-31	Astrazeneca Ab	Chemical process
JPWO2007020935A1 (ja) *	2005-08-17	2009-02-26	小野薬品工業株式会社	Ｐ２ｙ１２受容体および／またはｐ２ｙ１４受容体ブロッカーを含有してなる疼痛治療剤
TWI391378B (zh)	2006-03-16	2013-04-01	Astellas Pharma Inc	喹啉酮衍生物或其製藥學上可被容許之鹽
GB0615620D0 (en)	2006-08-05	2006-09-13	Astrazeneca Ab	A process for the preparation of optically active intermediates
TWI482772B (zh) *	2006-08-21	2015-05-01	Astrazeneca Ab	適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2008024044A1 (en) *	2006-08-21	2008-02-28	Astrazeneca Ab	Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
JP2010508350A (ja) *	2006-10-31	2010-03-18	ヤンセンファーマシューティカエヌ．ベー．	Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
TWI496776B (zh) *	2007-11-15	2015-08-21	Astrazeneca Ab	製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) *	2007-12-03	2013-02-11	Астразенека Аб	Спосіб лікування або запобігання аневризмі черевної аорти
TWI389913B (zh) *	2008-09-08	2013-03-21	Lg Life Sciences Ltd	并合雜環化合物
CN102149716A (zh) *	2008-09-09	2011-08-10	阿斯利康(瑞典)有限公司	制备[1S-[1α,2α,3β(1S，2R),5β]]-3-[7-[2-(3,4-二氟苯基)-环丙氨基]-5-(丙硫基)-3H-1,2,3-三唑并[4,5-d]嘧啶-3-基]-5-(2-羟乙氧基)环戊烷-1,2-二醇的方法及其中间体
WO2010043721A1 (en)	2008-10-17	2010-04-22	Oryzon Genomics, S.A.	Oxidase inhibitors and their use
WO2010084160A1 (en)	2009-01-21	2010-07-29	Oryzon Genomics S.A.	Phenylcyclopropylamine derivatives and their medical use
WO2011017108A2 (en)	2009-07-27	2011-02-10	Auspex Pharmaceuticals, Inc.	Cyclopropyl modulators of p2y12 receptor
EP2305376A1 (en)	2009-09-23	2011-04-06	Lonza Ltd.	Process and catalyst for the catalytic hydrogenation of aromatic and heteroaromatic nitro compounds
EP2480528B1 (en)	2009-09-25	2018-08-29	Oryzon Genomics, S.A.	Lysine specific demethylase-1 inhibitors and their use
US8946296B2 (en)	2009-10-09	2015-02-03	Oryzon Genomics S.A.	Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
CN102770434A (zh)	2009-12-03	2012-11-07	阿斯利康(瑞典)有限公司	三唑并[4,5-d]嘧啶血小板聚集抑制剂的共晶体
EP2633857B1 (en)	2009-12-23	2015-08-12	ratiopharm GmbH	Solid pharmaceutical dosage form of ticagrelor and acetylsalicylic acid
AU2011216991A1 (en)	2010-02-16	2012-08-30	Actavis Group Ptc Ehf	Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
US9616058B2 (en)	2010-02-24	2017-04-11	Oryzon Genomics, S.A.	Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
WO2011106106A2 (en)	2010-02-24	2011-09-01	Oryzon Genomics, S.A.	Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
EP2560947B1 (en)	2010-04-19	2016-10-12	Oryzon Genomics, S.A.	Lysine specific demethylase-1 inhibitors and their use
AU2011244023A1 (en)	2010-04-20	2012-10-25	Actavis Group Ptc Ehf	Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates
BR112012033500A2 (pt)	2010-06-30	2016-11-29	Actavis Group Hf	processo para a preparação de derivados de fenilciclopropilamina substiuídos, processo de vaso único para a preparação de derivados de fenilciclopropilamina substiuídos, formas de estado sólido de um sal de adição de ácido e processo para a preparação da forma de estado sólido de um sal de adição de ácido
CN104892525A (zh)	2010-07-29	2015-09-09	奥瑞泽恩基因组学股份有限公司	Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
EP2598480B1 (en)	2010-07-29	2019-04-24	Oryzon Genomics, S.A.	Cyclopropylamine derivatives useful as lsd1 inhibitors
US9061966B2 (en)	2010-10-08	2015-06-23	Oryzon Genomics S.A.	Cyclopropylamine inhibitors of oxidases
WO2012063126A2 (en)	2010-11-09	2012-05-18	Actavis Group Ptc Ehf	Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material
WO2012072713A2 (en)	2010-11-30	2012-06-07	Oryzon Genomics, S.A.	Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
CN103429576A (zh) *	2010-12-20	2013-12-04	阿特维斯集团公司	制备三唑并[4,5-d]嘧啶衍生物及其中间体的新方法
EP2712315B1 (en)	2011-02-08	2021-11-24	Oryzon Genomics, S.A.	Lysine demethylase inhibitors for myeloproliferative disorders
CN102653539B (zh) *	2011-03-01	2014-09-17	秦引林	一种抗血小板聚集化合物及其药物组合
US9056838B2 (en)	2011-04-06	2015-06-16	Teva Pharmaceutical Industries Ltd.	Intermediates and processes for preparing Ticagrelor
CN102731510B (zh) *	2011-04-07	2015-12-16	博瑞生物医药（苏州）股份有限公司	替卡格雷的衍生物、制备方法及其药物用途
CZ2011229A3 (cs)	2011-04-19	2012-08-15	Zentiva, K.S.	Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
BR112013028936B1 (pt)	2011-05-13	2021-10-19	Astrazeneca Ab	Processo para a preparação de benzil [(3as,4r,6s,6ar)-6-hidróxi-2,2-dimetiltetra-hidro- 3ahciclopenta[d]dioxol]-4-il]carbamato e compostos intermediários no processo
US20140329833A1 (en) *	2011-05-19	2014-11-06	Oryzon Genomics, S.A	Lysine demethylase inhibitors for inflammatory diseases or conditions
WO2012156537A2 (en) *	2011-05-19	2012-11-22	Oryzon Genomics, S.A.	Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
WO2012164286A1 (en)	2011-06-01	2012-12-06	Astrazeneca Ab	Novel ticagrelor co - crystal
WO2012172426A1 (en)	2011-06-15	2012-12-20	Actavis Group Ptc Ehf	Improved process for preparing cyclopentylamine derivatives and intermediates thereof
CN102924457A (zh) *	2011-08-12	2013-02-13	上海恒瑞医药有限公司	三唑并嘧啶类衍生物、其制备方法及其用途
US9221829B2 (en)	2011-09-14	2015-12-29	Lek Pharmaceuticals D.D.	Synthesis of triazolopyrimidine compounds
EP2570405A1 (en)	2011-09-14	2013-03-20	LEK Pharmaceuticals d.d.	Synthesis of Triazolopyrimidine Compounds
US9487512B2 (en)	2011-10-20	2016-11-08	Oryzon Genomics S.A.	(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
AU2012324805B2 (en)	2011-10-20	2017-04-13	Oryzon Genomics, S.A.	(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
EP2771326B1 (en)	2011-10-27	2017-12-20	LEK Pharmaceuticals d.d.	Synthesis of triazolopyrimidine compounds
EP2586773A1 (en)	2011-10-27	2013-05-01	LEK Pharmaceuticals d.d.	Synthesis of Triazolopyrimidine Compounds
EP2589587A1 (en)	2011-11-04	2013-05-08	Chemo Ibérica, S.A.	Synthesis of nitrogen substituted cyclopropanes
MX2014006190A (es)	2011-11-30	2014-07-10	Actavis Group Ptc Ehf	Nueva forma cristalina de ticagrelor y proceso para la preparacion de la misma.
EP2607355A1 (en) *	2011-12-23	2013-06-26	LEK Pharmaceuticals d.d.	Synthesis of triazolopyrimidine compounds
IN2014KN01491A (no) *	2011-12-23	2015-10-23	Lek Pharmaceuticals
EP2628721A1 (en)	2012-02-20	2013-08-21	LEK Pharmaceuticals d.d.	Synthesis of 2-(3,4-difluorophenyl)cyclopropanecarboxylic acid
WO2013144295A1 (en)	2012-03-30	2013-10-03	Sandoz Ag	Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts
EP2644590A1 (en)	2012-03-30	2013-10-02	LEK Pharmaceuticals d.d.	Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts
US9233966B2 (en)	2012-04-05	2016-01-12	Dr. Reddy's Laboratories Limited	Preparation of ticagrelor
WO2013163892A1 (en) *	2012-05-02	2013-11-07	Sunshine Lake Pharma Co., Ltd.	Novel triazolo pyrimidine compounds and a process of preparation thereof
CN102659815B (zh) *	2012-05-04	2013-07-17	开原亨泰制药股份有限公司	一种制备选择性抗凝血药替卡格雷及其中间体的方法
EP2666771A1 (en)	2012-05-24	2013-11-27	LEK Pharmaceuticals d.d.	Synthesis of Aminocyclopentanetriol Derivatives
ITMI20121142A1 (it) *	2012-06-28	2013-12-29	Chemo Iberica Sa	Processo chemoenzimatico per la produzione di fenil ciclopropilammine
EA024825B8 (ru) *	2012-06-29	2016-12-30	Зентива, К.С.	Сокристалл тикагрелора с 3-гидрокси-2-нафтойной кислотой, способ его получения и применение
CN104640864B (zh) *	2012-07-04	2016-11-16	力奇制药公司	替格瑞洛与二价金属盐的加合物
CN103626743B (zh) *	2012-08-23	2018-06-08	广东东阳光药业有限公司	替卡格雷的新型中间体及其制备方法
CN102875537A (zh) *	2012-09-10	2013-01-16	常州制药厂有限公司	一种新的抗血栓药物的制备方法
CZ2012705A3 (cs)	2012-10-16	2014-04-23	Zentiva, K.S.	Pevná orální farmaceutická formulace obsahující ticagrelor
WO2014083139A1 (en)	2012-11-29	2014-06-05	Actavis Group Ptc Ehf	Novel amorphous form of ticagrelor
IN2012MU03723A (no) *	2012-12-31	2015-07-10	Megafine Pharma P Ltd
CN104045620B (zh) *	2013-03-12	2017-05-10	博瑞生物医药（苏州）股份有限公司	一种替卡格雷中间体的制备方法
CZ307217B6 (cs)	2013-03-14	2018-04-04	Zentiva, K.S.	Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
IN2013MU01111A (no) *	2013-03-25	2015-05-01	Glenmark Generics Ltd
ITMI20130487A1 (it)	2013-03-29	2014-09-30	Chemo Res S L	Alchilazione selettiva di ciclopentilalcoli
CN104098553B (zh)	2013-04-10	2017-11-28	江苏恒瑞医药股份有限公司	替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP2813216A1 (en)	2013-06-10	2014-12-17	Zentiva, a.s.	Stabilized amorphous ticagrelor
WO2014170026A1 (en)	2013-04-18	2014-10-23	Zentiva, K.S.	Stabilized amorphous ticagrelor
CN104230818B (zh) *	2013-06-06	2018-01-12	郝聪梅	替卡格雷中间体的改进制备方法
EP2816043A1 (en)	2013-06-21	2014-12-24	LEK Pharmaceuticals d.d.	Spherical ticagrelor particles
WO2014206187A1 (zh)	2013-06-24	2014-12-31	苏州明锐医药科技有限公司	替卡格雷及其中间体的制备方法
CN104250251B (zh) *	2013-06-25	2017-05-17	上海京新生物医药有限公司	一种替格瑞洛的制备方法
WO2015001489A1 (en)	2013-07-01	2015-01-08	Ranbaxy Laboratories Limited	Pharmaceutical compositions of ticagrelor
CZ2013866A3 (cs)	2013-11-08	2015-05-20	Zentiva, K.S.	Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
WO2015110952A1 (en)	2014-01-21	2015-07-30	Wockhardt Limited	Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN103992323B (zh) *	2014-04-18	2017-03-29	南通常佑药业科技有限公司	一种替格瑞洛的制备方法
WO2015162630A1 (en)	2014-04-25	2015-10-29	Anlon Chemical Research Organization	Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
DE102014108210A1 (de)	2014-06-11	2015-12-17	Dietrich Gulba	Rodentizid
EP3157907B1 (en)	2014-06-18	2018-08-29	Flamma S.P.A.	Process for the preparation of triazolo[4,5-d]pyrimidine cyclopentane compounds
CN105272985B (zh) *	2014-06-24	2017-11-21	珠海联邦制药股份有限公司	三唑并[4,5‑d]嘧啶化合物及其合成方法、用途、组合物
WO2016001851A1 (en) *	2014-07-02	2016-01-07	Dr. Reddy's Laboratories Limited	Preparation of ticagrelor
KR102594117B1 (ko)	2014-10-01	2023-10-26	메디뮨 리미티드	티카그렐로에 대한 항체 및 이의 사용 방법
WO2016116942A1 (en)	2015-01-20	2016-07-28	Anlon Chemical Research Organization	Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105985346B (zh) *	2015-03-06	2019-10-18	苏州朗科生物技术股份有限公司	一种新的替格瑞洛化合物制备方法及其中间体化合物
US9789087B2 (en)	2015-08-03	2017-10-17	Thomas Jefferson University	PAR4 inhibitor therapy for patients with PAR4 polymorphism
CN105237540B (zh) *	2015-09-21	2017-10-03	南京正大天晴制药有限公司	一种替格瑞洛有关物质的制备方法、检测方法及用途
US20190002471A1 (en)	2016-01-05	2019-01-03	Amneal Pharmaceuticals Company Gmbh	Crystalline Form Of Ticagrelor
TR201601835A2 (tr)	2016-02-12	2017-08-21	Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi	Ti̇kagrelor i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇
US20170296666A1 (en)	2016-04-18	2017-10-19	Amneal Pharmaceuticals Company Gmbh	Stable Pharmaceutical Composition Of Amorphous Ticagrelor
EA201892150A1 (ru)	2016-04-21	2019-05-31	Астразенека Аб	Распадающиеся в полости рта таблетки
WO2018038265A1 (ja) *	2016-08-26	2018-03-01	田辺三菱製薬株式会社	二環式含窒素複素環化合物
US10905691B2 (en)	2016-09-09	2021-02-02	Université de Liège	Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
DK3292867T3 (da) *	2016-09-09	2019-07-22	Univ Liege	Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion
CN107814772A (zh) *	2017-11-24	2018-03-20	常州沃腾化工科技有限公司	4,6‑二氯‑5‑氨基‑2‑丙硫基嘧啶酯的精制方法
EP3527571A1 (en) *	2018-02-14	2019-08-21	Université de Liège	Pyrimidine derivatives for prevention and treatment of bacterial infection
EA202190328A1 (ru)	2018-07-27	2021-07-01	КРКА, д.д., НОВО МЕСТО	Фармацевтическая композиция, содержащая тикагрелор
CN109761785A (zh) *	2019-02-16	2019-05-17	安徽诺全药业有限公司	一种(1r，2r）-2-(3,4-二氟苯基)环丙烷羧酸的合成方法
GB201910656D0 (en)	2019-07-25	2019-09-11	Univ Liege	New use of triazolo(4,5-d)Pyrimidine deerivatives
EP3919497A1 (en)	2020-06-04	2021-12-08	Zaklady Farmaceutyczne Polpharma S.A.	Process for the preparation of ticagrelor
CN112876485A (zh) *	2021-01-25	2021-06-01	郭丽伟	一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
EP4070658A1 (de)	2021-04-06	2022-10-12	BIORoxx GmbH	Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
WO2023213198A1 (zh) *	2022-05-04	2023-11-09	华东师范大学	芳香稠环化合物作为trek-1激活剂的用途、包含其的药物组合物、镇痛剂

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3106578A (en)	1960-09-16	1963-10-08	Smith Kline French Lab	Nu-phenethyl-2-phenylcyclopropylamine derivatives
SE329623B (no)	1967-06-08	1970-10-19	C F Boehringer Soehne Gmbh
DE1670265A1 (de)	1967-08-25	1971-01-28	Boehringer Mannheim Gmbh	2-Amino-Adenosinderivate und Verfahren zu deren Herstellung
CH558137A (de)	1971-05-17	1975-01-31	Ciba Geigy Ag	Mittel zur beeinflussung des pflanzenwachstums.
US4016204A (en)	1975-10-31	1977-04-05	Nelson Research & Development Company	Method of synthesis of trans-2-phenylcyclopropylamine
US4543255A (en)	1984-05-10	1985-09-24	Southern Research Institute	Carbocyclic analogs of purine 2'-deoxyribofuranosides
US4742064A (en)	1985-09-10	1988-05-03	Regents Of The University Of Minnesota	Antiviral carbocyclic analogs of xylofuranosylpurines
PT89482B (pt)	1988-01-20	1994-02-28	Univ Minnesota	Processo para a preparacao de derivados de nucleosidos disesoxi-didesidro-carboxilico
CA2005192A1 (en)	1988-12-12	1990-06-12	Peter M. Palese	Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
US5110933A (en)	1989-11-13	1992-05-05	Board Of Regents Of Oklahoma State University	Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
US5652366A (en)	1990-09-25	1997-07-29	Rhone-Poulenc Rorer Pharmaceuticals Inc.	DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
AU665184B2 (en)	1991-01-23	1995-12-21	Gensia, Inc.	Adenosine kinase inhibitors
CA2107667A1 (en)	1991-04-06	1992-10-07	Anthony Howard Ingall	Atp analogues
EP0521463A3 (en)	1991-07-04	1993-04-14	Hoechst Aktiengesellschaft	Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
FI101150B (fi)	1991-09-09	1998-04-30	Sankyo Co	Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US5817660A (en)	1991-12-06	1998-10-06	Hoechst Marion Roussel, Inc.	Trans cyclopentanyl purine analogs useful as immunosuppressants
US5338725A (en)	1992-06-30	1994-08-16	The Research Foundation Of The State University Of New York	Anti-aggregatory agents for platelets
IL108523A0 (en)	1993-02-03	1994-05-30	Gensia Inc	Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
CN1042430C (zh)	1993-02-10	1999-03-10	英国阿斯特拉药品有限公司	N－烷基－2－取代的atp类似物、其制备方法和用途
US5688774A (en)	1993-07-13	1997-11-18	The United States Of America As Represented By The Department Of Health And Human Services	A3 adenosine receptor agonists
US5620676A (en)	1994-03-08	1997-04-15	The United States Of America As Represented By The Department Of Health And Human Services	Biologically active ATP analogs
US5831099A (en)	1995-03-10	1998-11-03	The United States Of America As Represented By The Secretary Of The Army	Compounds of 1,5-disubstituted-3,7 diaza bicyclo 3.3.0! octanes and products containing the same
US5712258A (en)	1995-03-23	1998-01-27	The Trustees Of The University Of Pennsylvania	Inotropic ADP and ATP analogues and their pharmaceutical compositions
US6143749A (en)	1995-06-07	2000-11-07	Abbott Laboratories	Heterocyclic substituted cyclopentane compounds
ATE217010T1 (de)	1995-07-11	2002-05-15	Astrazeneca Ab	Inhibitoren der plättchenaggregation
WO1997009330A1 (fr)	1995-09-01	1997-03-13	Hokuriku Seiyaku Co., Ltd.	Cristal d'hydrate et son procede de preparation
DE69632830T2 (de)	1995-11-21	2005-08-25	Euroscreen S.A.	Rezeptor und dafür kodierendes nukleinsäuremolekül
US5948437A (en)	1996-05-23	1999-09-07	Zeneca Limited	Pharmaceutical compositions using thiazepine
ATE213245T1 (de) *	1996-12-20	2002-02-15		Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
JPH10258654A (ja)	1997-03-18	1998-09-29	Delta Tsuuring:Kk	リクライニングシート
SE9702772D0 (sv)	1997-07-22	1997-07-22	Astra Pharma Prod	Novel compounds
SE9702773D0 (sv)	1997-07-22	1997-07-22	Astra Pharma Prod	Novel compounds
AR017014A1 (es)	1997-07-22	2001-08-22	Astrazeneca Ab	Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
SE9702775D0 (sv)	1997-07-22	1997-07-22	Astra Pharma Prod	Novel compounds
SE9704709D0 (sv)	1997-12-17	1997-12-17	Astra Ab	Pharmaceutically active compounds
TWI229674B (en)	1998-12-04	2005-03-21	Astra Pharma Prod	Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
DE60020010T2 (de)	1999-06-21	2006-01-19	Yamamoto Chemicals, Inc., Yao	Polymethinverbindungen, Verfahren zu deren Herstellung und deren Verwendung
SE9903759D0 (sv)	1999-10-18	1999-10-18	Astra Ab	Pharmaceutically active compounds
HUP0203371A3 (en)	1999-11-12	2005-02-28	Biogen Idec Ma Inc Cambridge	Adenosine receptor antagonists and methods of making and using the same
GB0013407D0 (en)	2000-06-02	2000-07-26	Astrazeneca Ab	Forms of a chemical compound
US7040429B2 (en)	2001-10-10	2006-05-09	Invacare Corporation	Wheelchair suspension
PL371259A1 (en)	2001-12-21	2005-06-13	Pfizer Products Inc.	Directly compressible formulations of azithromycin
TWI482772B (zh)	2006-08-21	2015-05-01	Astrazeneca Ab	適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
CN102149716A (zh)	2008-09-09	2011-08-10	阿斯利康(瑞典)有限公司	制备[1S-[1α,2α,3β(1S，2R),5β]]-3-[7-[2-(3,4-二氟苯基)-环丙氨基]-5-(丙硫基)-3H-1,2,3-三唑并[4,5-d]嘧啶-3-基]-5-(2-羟乙氧基)环戊烷-1,2-二醇的方法及其中间体
AU2011216991A1 (en)	2010-02-16	2012-08-30	Actavis Group Ptc Ehf	Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
BR112012033500A2 (pt)	2010-06-30	2016-11-29	Actavis Group Hf	processo para a preparação de derivados de fenilciclopropilamina substiuídos, processo de vaso único para a preparação de derivados de fenilciclopropilamina substiuídos, formas de estado sólido de um sal de adição de ácido e processo para a preparação da forma de estado sólido de um sal de adição de ácido
CN103429576A (zh)	2010-12-20	2013-12-04	阿特维斯集团公司	制备三唑并[4,5-d]嘧啶衍生物及其中间体的新方法
US9056838B2 (en)	2011-04-06	2015-06-16	Teva Pharmaceutical Industries Ltd.	Intermediates and processes for preparing Ticagrelor
WO2012172426A1 (en)	2011-06-15	2012-12-20	Actavis Group Ptc Ehf	Improved process for preparing cyclopentylamine derivatives and intermediates thereof
MX2014006190A (es)	2011-11-30	2014-07-10	Actavis Group Ptc Ehf	Nueva forma cristalina de ticagrelor y proceso para la preparacion de la misma.
US9233966B2 (en)	2012-04-05	2016-01-12	Dr. Reddy's Laboratories Limited	Preparation of ticagrelor
WO2014083139A1 (en)	2012-11-29	2014-06-05	Actavis Group Ptc Ehf	Novel amorphous form of ticagrelor
IN2012MU03723A (no)	2012-12-31	2015-07-10	Megafine Pharma P Ltd
WO2014118808A2 (en)	2013-02-04	2014-08-07	Hetero Research Foundation	Ticagrelor solid dispersion
CN104098553B (zh)	2013-04-10	2017-11-28	江苏恒瑞医药股份有限公司	替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP3004113A2 (en)	2013-06-04	2016-04-13	Dr. Reddy's Laboratories Ltd.	Preparation of ticagrelor
WO2016001851A1 (en)	2014-07-02	2016-01-07	Dr. Reddy's Laboratories Limited	Preparation of ticagrelor
EP3730142A1 (en)	2015-01-27	2020-10-28	Astrazeneca	Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction

1999
- 1999-11-19 TW TW088120241A patent/TWI229674B/zh not_active IP Right Cessation
- 1999-12-02 ID IDW00200101173A patent/ID29927A/id unknown
- 1999-12-02 US US14/976,977 patent/USRE46276E1/en not_active Expired - Lifetime
- 1999-12-02 KR KR1020067015291A patent/KR100776484B1/ko active IP Right Grant
- 1999-12-02 DK DK03025536T patent/DK1386921T3/da active
- 1999-12-02 KR KR1020067027016A patent/KR100822602B1/ko active IP Right Grant
- 1999-12-02 ES ES03025536T patent/ES2318081T3/es not_active Expired - Lifetime
- 1999-12-02 CZ CZ20041089A patent/CZ300280B6/cs not_active IP Right Cessation
- 1999-12-02 SI SI9930550T patent/SI1135391T1/xx unknown
- 1999-12-02 DK DK99963796T patent/DK1135391T3/da active
- 1999-12-02 TR TR2001/01567T patent/TR200101567T2/xx unknown
- 1999-12-02 EG EG154399A patent/EG24814A/xx active
- 1999-12-02 SK SK749-2001A patent/SK286007B6/sk not_active IP Right Cessation
- 1999-12-02 RU RU2001118284/04A patent/RU2317990C2/ru active Protection Beyond IP Right Term
- 1999-12-02 AT AT99963796T patent/ATE261970T1/de active
- 1999-12-02 PT PT03025536T patent/PT1386921E/pt unknown
- 1999-12-02 EP EP03025537A patent/EP1386909A1/en not_active Withdrawn
- 1999-12-02 CN CN99815926A patent/CN1128801C/zh not_active Ceased
- 1999-12-02 AU AU20165/00A patent/AU766618B2/en not_active Expired
- 1999-12-02 HU HU0105081A patent/HU228589B1/hu active Protection Beyond IP Right Term
- 1999-12-02 DE DE201112100004 patent/DE122011100004I1/de active Pending
- 1999-12-02 KR KR1020017006907A patent/KR100742924B1/ko active IP Right Review Request
- 1999-12-02 JP JP2000586728A patent/JP4202607B2/ja not_active Expired - Lifetime
- 1999-12-02 ES ES99963796T patent/ES2216623T3/es not_active Expired - Lifetime
- 1999-12-02 PL PL348724A patent/PL201283B1/pl unknown
- 1999-12-02 EP EP03025535A patent/EP1386917B1/en not_active Expired - Lifetime
- 1999-12-02 EP EP03025536A patent/EP1386921B1/en not_active Expired - Lifetime
- 1999-12-02 DE DE69915675A patent/DE69915675D1/de not_active Expired - Lifetime
- 1999-12-02 WO PCT/SE1999/002256 patent/WO2000034283A1/en active Search and Examination
- 1999-12-02 CZ CZ20011962A patent/CZ295234B6/cs unknown
- 1999-12-02 BR BRPI9915883A patent/BRPI9915883B8/pt not_active IP Right Cessation
- 1999-12-02 MY MYPI99005232A patent/MY121867A/en unknown
- 1999-12-02 DK DK03025535.0T patent/DK1386917T3/da active
- 1999-12-02 KR KR1020077014185A patent/KR100764417B1/ko active IP Right Grant
- 1999-12-02 DE DE69915675T patent/DE69915675T4/de not_active Expired - Lifetime
- 1999-12-02 SI SI9931026T patent/SI1386921T1/sl unknown
- 1999-12-02 SI SI9931059T patent/SI1386917T1/sl unknown
- 1999-12-02 ES ES03025535T patent/ES2366902T3/es not_active Expired - Lifetime
- 1999-12-02 AT AT03025535T patent/ATE513816T1/de active
- 1999-12-02 CZ CZ20080600A patent/CZ300373B6/cs not_active IP Right Cessation
- 1999-12-02 EP EP10183113A patent/EP2322513A3/en not_active Withdrawn
- 1999-12-02 DE DE69940171T patent/DE69940171D1/de not_active Expired - Lifetime
- 1999-12-02 PT PT99963796T patent/PT1135391E/pt unknown
- 1999-12-02 IL IL14323299A patent/IL143232A0/xx unknown
- 1999-12-02 NZ NZ511778A patent/NZ511778A/en not_active IP Right Cessation
- 1999-12-02 AT AT03025536T patent/ATE418547T1/de active
- 1999-12-02 CA CA2351709A patent/CA2351709C/en not_active Expired - Lifetime
- 1999-12-02 US US09/508,195 patent/US6525060B1/en not_active Ceased
- 1999-12-02 EP EP99963796A patent/EP1135391B1/en not_active Expired - Lifetime
- 1999-12-03 AR ARP990106165A patent/AR023920A1/es not_active Application Discontinuation
- 1999-12-27 SA SA99200848A patent/SA99200848B1/ar unknown
2001
- 2001-05-17 IL IL143232A patent/IL143232A/en active Protection Beyond IP Right Term
- 2001-05-18 ZA ZA200104094A patent/ZA200104094B/en unknown
- 2001-06-01 NO NO20012725A patent/NO319806B1/no active Protection Beyond IP Right Term
2002
- 2002-02-19 HK HK04104367.3A patent/HK1061246A1/xx unknown
- 2002-02-19 HK HK02101198.6A patent/HK1039933B/zh unknown
- 2002-12-20 US US10/323,655 patent/US6974868B2/en not_active Expired - Lifetime
2004
- 2004-06-28 HK HK04104617.1A patent/HK1061684A1/xx unknown
2005
- 2005-06-06 IL IL169013A patent/IL169013A/en not_active IP Right Cessation
- 2005-09-21 US US11/230,493 patent/US7250419B2/en not_active Expired - Lifetime
2006
- 2006-10-18 JP JP2006283455A patent/JP2007084551A/ja not_active Ceased
2007
- 2007-01-10 AR ARP070100095A patent/AR058967A2/es active IP Right Grant
- 2007-02-28 US US11/711,838 patent/US20070265282A1/en not_active Abandoned
- 2007-06-14 IL IL183969A patent/IL183969A/en not_active IP Right Cessation
- 2007-09-11 RU RU2007133926/04A patent/RU2007133926A/ru not_active Application Discontinuation
2008
- 2008-05-08 US US12/149,771 patent/US20080214812A1/en not_active Abandoned
- 2008-05-23 JP JP2008135275A patent/JP5043749B2/ja not_active Expired - Lifetime
2009
- 2009-02-26 CY CY20091100225T patent/CY1110501T1/el unknown
- 2009-04-06 IL IL198040A patent/IL198040A/en not_active IP Right Cessation
- 2009-08-11 AR ARP090103085A patent/AR072756A2/es active IP Right Grant
- 2009-11-18 US US12/591,395 patent/US20100069408A1/en not_active Abandoned
2010
- 2010-09-08 JP JP2010200486A patent/JP5415383B2/ja not_active Expired - Lifetime
- 2010-12-30 IL IL210398A patent/IL210398A0/en unknown
2011
- 2011-05-18 CY CY2011005C patent/CY2011005I1/el unknown
- 2011-05-23 NO NO2011007C patent/NO2011007I2/no unknown
- 2011-05-23 FR FR11C0016C patent/FR11C0016I2/fr active Active
- 2011-05-25 LT LTPA2011004C patent/LTPA2011004I1/lt unknown
- 2011-05-31 LU LU91819C patent/LU91819I2/fr unknown
- 2011-07-21 US US13/137,125 patent/US20120165348A1/en not_active Abandoned
- 2011-08-17 CY CY20111100786T patent/CY1111759T1/el unknown
2012
- 2012-03-19 US US13/423,848 patent/US20130072503A1/en not_active Abandoned
- 2012-05-25 RU RU2012121883/04A patent/RU2593201C2/ru active
- 2012-10-31 US US13/665,241 patent/US20130109702A1/en not_active Abandoned
2013
- 2013-09-05 HU HUS1300048C patent/HUS1300048I1/hu unknown
- 2013-10-31 US US14/068,942 patent/US20140296258A1/en not_active Abandoned
2014
- 2014-06-20 US US14/310,315 patent/US20150152111A1/en not_active Abandoned
2022
- 2022-03-23 NO NO2022007C patent/NO2022007I1/no unknown

Also Published As

Publication number	Publication date
PL348724A1 (en)	2002-06-03
TR200101567T2 (tr)	2001-12-21
AU766618B2 (en)	2003-10-23
IL210398A0 (en)	2011-03-31
SI1135391T1 (en)	2004-08-31
KR20070007971A (ko)	2007-01-16
US20130109702A1 (en)	2013-05-02
US20030144305A1 (en)	2003-07-31
IL143232A0 (en)	2002-04-21
HK1061246A1 (en)	2004-09-10
CY1110501T1 (el)	2015-04-29
US6974868B2 (en)	2005-12-13
IL169013A (en)	2015-10-29
IL198040A0 (en)	2009-12-24
ZA200104094B (en)	2002-08-19
NO20012725D0 (no)	2001-06-01
ATE261970T1 (de)	2004-04-15
BRPI9915883B8 (pt)	2021-05-25
JP2002531567A (ja)	2002-09-24
EP1386917B1 (en)	2011-06-22
SK7492001A3 (en)	2002-01-07
DK1386917T3 (da)	2011-08-29
LTC1135391I2 (lt)	2022-04-11
AR058967A2 (es)	2008-03-05
KR20010081054A (ko)	2001-08-25
SI1386917T1 (sl)	2011-09-30
CN1334816A (zh)	2002-02-06
HUS1300048I1 (hu)	2017-03-28
PL201283B1 (pl)	2009-03-31
RU2317990C2 (ru)	2008-02-27
RU2012121883A (ru)	2013-11-27
LU91819I2 (fr)	2011-08-01
CZ300280B6 (cs)	2009-04-08
EP1386909A1 (en)	2004-02-04
CY2011005I2 (el)	2014-04-09
ATE418547T1 (de)	2009-01-15
AR072756A2 (es)	2010-09-22
KR100776484B1 (ko)	2007-11-28
JP2011016831A (ja)	2011-01-27
CZ295234B6 (cs)	2005-06-15
US20060025590A1 (en)	2006-02-02
NO2011007I1 (no)	2011-06-06
AU2016500A (en)	2000-06-26
IL183969A0 (en)	2009-02-11
FR11C0016I1 (no)	2011-07-08
KR20070086540A (ko)	2007-08-27
CY1111759T1 (el)	2015-10-07
DK1135391T3 (da)	2004-06-28
CA2351709C (en)	2010-04-06
HK1039933B (zh)	2004-10-08
HUP0105081A3 (en)	2004-11-29
SA99200848B1 (ar)	2006-11-04
JP5043749B2 (ja)	2012-10-10
USRE46276E1 (en)	2017-01-17
RU2007133926A (ru)	2009-03-20
RU2593201C2 (ru)	2016-08-10
US20070265282A1 (en)	2007-11-15
EP2322513A2 (en)	2011-05-18
US20140296258A1 (en)	2014-10-02
HU228589B1 (en)	2013-04-29
PT1386921E (pt)	2009-02-23
NZ511778A (en)	2003-10-31
JP5415383B2 (ja)	2014-02-12
MY121867A (en)	2006-02-28
ES2216623T3 (es)	2004-10-16
ES2318081T3 (es)	2009-05-01
EP1386917A1 (en)	2004-02-04
NO2022007I1 (no)	2022-03-23
HK1039933A1 (en)	2002-05-17
DE69915675T2 (de)	2005-02-17
HK1061684A1 (en)	2004-09-30
EP1386921B1 (en)	2008-12-24
BRPI9915883B1 (pt)	2015-08-18
US20100069408A1 (en)	2010-03-18
EP1135391A1 (en)	2001-09-26
KR100822602B1 (ko)	2008-04-16
ATE513816T1 (de)	2011-07-15
ES2366902T3 (es)	2011-10-26
FR11C0016I2 (fr)	2012-03-16
IL143232A (en)	2008-12-29
US20150152111A1 (en)	2015-06-04
EP2322513A3 (en)	2011-08-24
EP1386921A1 (en)	2004-02-04
US6525060B1 (en)	2003-02-25
PT1135391E (pt)	2004-07-30
DK1386921T3 (da)	2009-03-23
HUP0105081A2 (hu)	2002-05-29
NO319806B1 (no)	2005-09-19
KR100764417B1 (ko)	2007-10-05
CY2011005I1 (el)	2014-04-09
IL198040A (en)	2015-06-30
EP1135391B1 (en)	2004-03-17
SI1386921T1 (sl)	2009-04-30
CN1128801C (zh)	2003-11-26
ID29927A (id)	2001-10-25
CZ300373B6 (cs)	2009-05-06
NO20012725L (no)	2001-07-31
TWI229674B (en)	2005-03-21
DE69915675D1 (de)	2004-04-22
SK286007B6 (sk)	2008-01-07
US7250419B2 (en)	2007-07-31
JP4202607B2 (ja)	2008-12-24
KR100742924B1 (ko)	2007-07-25
AR023920A1 (es)	2002-09-04
KR20060091056A (ko)	2006-08-17
DE69915675T4 (de)	2012-08-30
US20080214812A1 (en)	2008-09-04
JP2008266345A (ja)	2008-11-06
WO2000034283A1 (en)	2000-06-15
BR9915883A (pt)	2001-08-21
US20120165348A1 (en)	2012-06-28
EG24814A (en)	2010-09-21
US20130072503A1 (en)	2013-03-21
LTPA2011004I1 (lt)	2022-04-11
IL183969A (en)	2011-03-31
DE69940171D1 (de)	2009-02-05
JP2007084551A (ja)	2007-04-05
CZ20011962A3 (cs)	2001-11-14
CA2351709A1 (en)	2000-06-15
DE122011100004I1 (de)	2011-09-08

Publication	Publication Date	Title
NO2022007I1 (no)	2022-03-23	Ticagrelor eller et farmasøytisk akseptabelt salt derav - forlenget SPC
NO2018014I2 (no)	2018-11-19	Deferasirox eller et farmasøytisk akseptabelt salt derav
NO2009023I2 (no)	2012-12-03	Retapamulin eller farmasøytisk akseptabelt salt derav
NO2015026I2 (no)	2015-12-28	panobinostat eller et farmasøytisk akseptabelt salt derav
NO2009007I2 (no)	2010-06-07	Robenakoksib, eller et farmasøytisk akseptabelt salt derav, eller en farmasøytisk akseptabel in vivo hydrolyserbar ester derav
NO2009004I2 (no)	2010-08-16	Mavacoxib eller et farmasøytisk akseptabelt salt derav
NO2009028I2 (no)	2011-10-17	Gefitinib eller et farmasøytisk akseptabelt salt derav
IS5425A (is)	2000-03-31	Læknislyf
EE200000438A (et)	2001-12-17	Farmatseutiliselt aktiivne morfolinool
NO20002447L (no)	2000-07-06	Inhalasjonsanordning
DE69832369D1 (de)	2005-12-22	Hämofiltrationssystem
NO20001160D0 (no)	2000-03-07	Nytt skumdannende farmasøytisk preparat
NO20012116L (no)	2001-07-02	Vitamin D analoger
NO20005218L (no)	2000-11-10	Farmasöytisk aerosolpreparat
IS5869A (is)	2001-02-28	Hraðlosandi tafla
NO980546D0 (no)	1998-02-09	Farmasöytiske midler
NO2010003I1 (no)	2010-03-05	Prukaloprid eller et farmasøytisk aksepterbart syreaddisjonssalt derav
ATE432707T1 (de)	2009-06-15	Pharmazeutische zubereitung
ATE218362T1 (de)	2002-06-15	Ifnnar/ifn komplex
EE9900545A (et)	2000-06-15	Farmatseutiline kompositsioon
NO970503L (no)	1998-08-05	Hudpreparat
NO995492D0 (no)	1999-11-10	Algicider
EP0998924A4 (en)	2007-05-02	ANTI-TUMOR ACTIVE
DE59809325D1 (de)	2003-09-25	Rollenschneidvorrichtung
ATA77096A (de)	1998-05-15	Pharmazeutische präparation